Ian Bouligny, MD

Peer-Reviewed Articles

1. Bazinet, A, Bataller Torralba, A, Chien, KS, Sasaki, K, Montalban Bravo, G, Hammond, DE, Bouligny, IM, Swaminathan, M, Jen, WY, Kugler, E, Kanagal Shamanna, R, Kadia, TM, Borthakur, G, DiNardo, C, Short, NJ, Pemmaraju, N, Jabbour, EJ, Daver, N, Ravandi-Kashani, F, Urrutia, S, Gener-Ricos, G, Braish, J, Briski, RE, Rodriguez-Sevilla, JJ, Li, Z, Champlin, RE, Shpall, E, Alousi, AM, Oran, B, Hosing, C, Ramdial, JL, Olson, AL, Pierce, S, Chen, J, Kantarjian, HM, Garcia-Manero, G, Popat, UR. Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes. Blood cancer journal 16(1), 2026. e-Pub 2026. PMID: 41896225.
2. Kadia TM, Bataller A, Bazinet A, Borthakur G, Daver N, Short NJ, DiNardo C, Jabbour E, Rausch CR, Issa GC, Pemmaraju N, Ohanian M, Maiti A, Montalban-Bravo G, Sasaki K, Bouligny IM, Yilmaz M, Haddad FG, Masarova L, Chien K, Alvarado Y, Jain N, Popat U, Shpall E, Loghavi S, Qiao W, Wang X, Garcia-Manero G, Ravandi F, Kantarjian HM. Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia. Am J Hematol 101(7):1737-1747, 2026. e-Pub 2026. PMID: 42035228.
3. Vegivinti CTR, Montalban-Bravo G, Chien K, Hammond D, Sasaki K, Bataller A, Bouligny I, Jen WY, Swaminathan M, Loghavi S, Popat U, Garcia-Manero G, Bazinet A. Outcomes of patients diagnosed with myelodysplastic syndrome or acute myeloid leukemia following solid organ transplantation. Haematologica, 2026. e-Pub 2026. PMID: 42131946.
4. Montalban-Bravo G, Wu C, Rodriguez-Sevilla JJ, Wei Y, Chien KS, Bouligny I, Kanagal-Shamanna R, Li Z, Natu A, Gurney M, Bazinet A, Hammond D, Bataller A, Borthakur G, Short NJ, DiNardo CD, Kadia TM, Ravandi F, Daver N, Pemmaraju N, Jabbour E, Issa GC, Wang SA, Patel KP, Tang G, Medeiros LJ, Lasho TL, Finke CM, Al-Kali A, Csizmar CM, Alkhateeb H, Gangat N, Mangaonkar AA, Roman-Bravo D, Arenillas L, Tefferi A, Kantarjian HM, Garcia-Manero G, Calvo X, Patnaik MM, Loghavi S. Incorporation of genomic determinants improves diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemia. Blood Cancer Discov, 2026. e-Pub 2026. PMID: 41587375.
5. Chien KS, Loghavi S, Sasaki K, McCue D, Daver NG, Kadia TM, Ravandi F, Short NJ, Issa GC, Montalban-Bravo G, Haddad FG, Hammond DE, Swaminathan M, Bazinet A, Bataller A, Bouligny I, Pierce SA, Garcia-Manero G, Kantarjian HM, DiNardo CD. Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib. Clin Lymphoma Myeloma Leuk 26(2):e223-e228.e3, 2025. e-Pub 2025. PMID: 41469316.
6. Bataller Torralba, A, Sasaki, K, Urrutia, S, Montalban Bravo, G, Bazinet, A, Chien, KS, Hammond, DE, Bouligny, IM, Swaminathan, M, Issa, GC, Short, NJ, Daver, N, DiNardo, C, Kadia, TM, Jabbour, EJ, Ravandi-Kashani, F, Roboz, G, Savona, MR, Griffiths, EA, McCloskey, J, Odenike, O, Oganesian, A, Keer, HN, Azab, M, Kantarjian, HM, Garcia-Manero, G. Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 40164584.
7. Croden J, Jen WY, Marvin-Peek J, Xiao L, Bouligny IM, Loghavi S, Borthakur G, Daver NG, Abbas HA, Takahashi K, Sasaki K, Pemmaraju N, Short NJ, Hammond D, Jabbour E, Masarova L, Chien KS, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Alvarado-Valero Y, Garcia-Manero G, Ravandi F, Konopleva MY, Kantarjian HM, Kadia TM, DiNardo CD. Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax. Leukemia 39(10):2538-2541, 2025. e-Pub 2025. PMID: 40813623.
8. Jen WY, Tang G, Kugler E, Croden J, Sasaki K, Bazinet A, Bataller A, Montalban-Bravo G, Borthakur G, Toruner GA, Loghavi S, Short NJ, Issa GC, Bouligny IM, Pierce S, Popat U, Pemmaraju N, Jabbour E, Garcia-Manero G, Bhalla K, Ravandi F, Daver NG, DiNardo CD, Kantarjian HM, Kadia TM. MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia. Br J Haematol 207(6):2451-2461, 2025. e-Pub 2025. PMID: 40983567.
9. Bazinet A, Montalban-Bravo G, Bataller A, Hammond D, Loghavi S, Chien K, Sasaki K, Bouligny I, Swaminathan M, Jen WY, Popat U, Kadia T, DiNardo C, Jabbour E, Short N, Daver N, Ravandi F, Garcia-Manero G. Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndrome. Leukemia 39(11):2820-2824, 2025. e-Pub 2025. PMID: 40913105.
10. Bazinet, A, Loghavi, S, Wei, Y, Bataller Torralba, A, Sasaki, K, Arani, N, Darbaniyan, F, Chien, KS, Hammond, DE, Bouligny, IM, Kanagal Shamanna, R, Thongon, N, Tang, G, Urrutia, S, Kadia, TM, DiNardo, C, Daver, N, Short, NJ, Issa, GC, Pemmaraju, N, Jabbour, EJ, Wang, S, Wang, W, Borthakur, G, Bueso-Ramos, CE, Ravandi-Kashani, F, Medeiros, LJ, Kantarjian, HM, Garcia-Manero, G, Montalban Bravo, G. Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy. Leukemia 39(9):2256-2265, 2025. e-Pub 2025. PMID: 40691503.
11. Bataller Torralba, A, Goulart, H, Issa, GC, DiNardo, C, Daver, N, Kadia, TM, Bazinet, A, Bouligny, IM, Senapati, J, Haddad, FG, Borthakur, G, Sasaki, K, Short, NJ, Yilmaz, M, Montalban Bravo, G, Tang, G, Loghavi, S, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM, Jabbour, EJ. Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements. Leukemia 39(7):1640-1649, 2025. e-Pub 2025. PMID: 40346311.
12. Bazinet, A, Bataller Torralba, A, Kadia, TM, Daver, N, Short, NJ, Yilmaz, M, Sasaki, K, DiNardo, C, Borthakur, G, Issa, GC, Bouligny, IM, Pierce, S, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM. A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia. Cancer 131(6), 2025. e-Pub 2025. PMID: 40097915.
13. Bouligny IM, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Kornblau S, Kadia T, Masarova L, Takahashi K, Andreeff M, Bazinet A, Yang H, Kanagal-Shamanna R, Hosing C, Pierce S, Meyer M, Huang X, Garcia-Manero G. A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome. Haematologica 110(7):1628-1633, 2025. e-Pub 2025. PMID: 39973365.
14. Bouligny IM, DiNardo CD. Oral decitabine-cedazuridine in acute myeloid leukaemia. Br J Haematol 205(5):1674-1676, 2024. e-Pub 2024. PMID: 39313925.
15. Murray GF, Bouligny IM, Ho T, Gor J, Zacholski K, Wages NA, Grant S, Maher KR. Clonal Evolution in 207 Cases of Refractory or Relapsed Acute Myeloid Leukemia. Eur J Haematol 114(1):98-104, 2024. e-Pub 2024. PMID: 39315590.
16. Bouligny IM, Murray G, Doyel M, Patel T, Boron J, Tran V, Gor J, Hang Y, Alnimer Y, Ho T, Zacholski K, Venn C, Wages NA, Grant S, Maher KR. Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia. Med Oncol 41(3):80, 2024. e-Pub 2024. PMID: 38396145.
17. Bouligny IM, Murray G, Ho T, Doyel M, Patel T, Boron J, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Wages NA, Grant S, Maher KR. Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia. Res Sq, 2023. e-Pub 2023. PMID: 37398154.
18. Bouligny IM, Murray G, Doyel M, Patel T, Boron J, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Wages NA, Grant S, Maher KR. Venetoclax with decitabine or azacitidine in the first-line treatment of acute myeloid leukemia. EJHaem 4(2):381-392, 2023. e-Pub 2023. PMID: 37206255.
19. Bouligny IM, Maher KR, Grant S. Augmenting Venetoclax Activity Through Signal Transduction in AML. J Cell Signal 4(1):1-12, 2023. e-Pub 2023. PMID: 36911757.
20. Bouligny IM, Mehta V, Isom S, Ellis LR, Bhave RR, Howard DS, Lyerly S, Manuel M, Dralle S, Powell BL, Pardee TS. Efficacy of 10-day decitabine in acute myeloid leukemia. Leuk Res 103:106524, 2021. e-Pub 2021. PMID: 33640708.

Review Articles

1. Bouligny IM, Maher KR, Grant S. Secondary-Type Mutations in Acute Myeloid Leukemia: Updates from ELN 2022. Cancers (Basel) 15(13), 2023. e-Pub 2023. PMID: 37444402.
2. Bouligny IM, Maher KR, Grant S. Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives. Blood Rev 57:100996, 2023. e-Pub 2023. PMID: 35989139.
3. Maher KR, Bouligny IM, Yeager AM. Prevention and management of infections after exposure to ionizing radiation. J Radiol Prot 41(4), 2021. e-Pub 2021. PMID: 34265748.

Abstracts

1. Doyel M, Bouligny IM, Murray G, Patel T, Boron J, Tran V, Gor J, Hang Y, Ho T, Zacholski K, Venn CM, Alnimer YM, Wages N, Grant S, Maher KR. The impact of secondary-type mutations in newly diagnosed acute myeloid leukemia treated with venetoclax and decitabine or azacitidine. ASCO 41(16). e-Pub 2023.
2. Murray G, Bouligny IM, Patel T, Doyel M, Boron J, Tran V, Gor J, Hang Y, Ho T, Zacholski K, Venn CM, Alnimer YM, Wages N, Grant S, Maher KR. IDH inhibitors or chemotherapy in relapsed or refractory IDHmut acute myeloid leukemia. ASCO 41(16). e-Pub 2023.
3. Tran V, Bouligny IM, Murray G, Patel T, Doyel M, Boron J, Gor J, Hang Y, Ho T, Zacholski K, Venn CM, Alnimer YM, Wages N, Grant S, Maher KR. FLAG-IDA or venetoclax in previously treated TP53mut acute myeloid leukemia. ASCO 41(16). e-Pub 2023.
4. Murray G, Bouligny IM, Patel T, Doyel M, Boron J, Tran V, Gor J, Hang Y, Ho T, Zacholski K, Venn CM, Alnimer YM, Wages N, Grant S, Maher KR. Gilteritinib or venetoclax in relapsed or refractory FLT3mut acute myeloid leukemia. ASCO 41(16). e-Pub 2023.
5. Bouligny IM, Murray G, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Maher K. Back in JAK - Real-World Analysis of JAKmut AML. Blood 140(1):11812–11813, 2022. e-Pub 2022.
6. Bouligny IM, Murray G, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Maher K. IDH1/2mut for the Win: Comprehensive Molecular Stratification of Venetoclax in Combination with Hypomethylating Agents in AML. ASH 140(1):6335–6336. e-Pub 2022.
7. Bouligny IM, Murray G, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Maher K. CPX-351 Appears Superior to 7+3 in Adverse-Risk AML and AML-MRC. ASH 140(1):11745–11746. e-Pub 2022.
8. Bouligny IM, Murray G, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Maher K. Healthcare Disparities Among Minorities Treated with Venetoclax and Hypomethylating Agents in AML. ASH 140(1):13305–13306. e-Pub 2022.
9. Zacholski K, Bouligny IM, Venn CM, Tran V, Alnimer YM, Ho T, Maher KR. Analysis of real-world outcomes of IKZFmut in Philadelphia chromosome-positive ALL: A retrospective, single-institution experience. ASCO 40(16). e-Pub 2022.
10. Bouligny IM, Tran V, Zacholski K, Venn CM, Alnimer YM, Ho T, Maher KR. Retrospective analysis of healthcare disparities in Philadelphia chromosome-positive ALL: A single-institution experience of a large metropolitan area. ASCO 40(16). e-Pub 2022.
11. Tran V, Bouligny IM, Zacholski K, Venn CM, Alnimer YM, Ho T, Maher KR. Efficacy and safety of high-intensity versus reduced-intensity induction in Philadelphia chromosome-positive all ineligible for HSCT. ASCO 40(16). e-Pub 2022.
12. Venn CM, Zacholski K, Tran V, Alnimer YM, Ho T, Maher KR, Bouligny IM. Retrospective analysis of toxicities and clinical outcomes with BCR-ABL1 tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia. ASCO 40(16). e-Pub 2022.
13. Bouligny I, Maher KR. Re-induction with venetoclax in combination with hypomethylating agents (HMAs) versus FLAG-IDA in relapsed or refractory AML. ASCO. e-Pub 2022.
14. Maher KR, Bouligny I. Outcomes stratified by molecular aberration following induction with daunorubicin 60 mg/m2 versus daunorubicin 90 mg/m2 in AML. ASCO 40(16). e-Pub 2022.
15. Maher KR, Bouligny I. Molecular stratification of response and survival of venetoclax in combination with hypomethylating agents in AML. ASCO 40(16). e-Pub 2022.
16. Tran V, Bouligny IM, Alnimer YM, Zacholski K, Venn CM, Ho T, Maher KR. Impact of TKI combination therapy and MRD negativity on outcomes in Philadelphia chromosome-positive ALL: A retrospective, single-center experience. ASCO. e-Pub 2022.
17. Alnimer YM, Bouligny IM, Zacholski K, Venn CM, Tran V, Ho T, Maher KR. Efficacy and safety of asparagine-depleting regimens versus HyperCVAD in adults with Philadelphia chromosome-positive B-ALL: A retrospective analysis. ASCO 40(16). e-Pub 2022.
18. Bouligny IM, Murray G, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Maher K. Outcomes of FLAG-IDA Versus MEC in Relapsed or Refractory AML. Blood 140(Supplement 1):11742–11743, 2022. e-Pub 2022.
19. Bouligny IM, Murray G, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Maher K. Efficacy of Hypomethylating Agents with Venetoclax in TP53mut AML. Blood 140(1):11842–11843, 2022. e-Pub 2022.
20. Bouligny IM, Murray G, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Maher K. Real-World Safety and Efficacy of Gemtuzumab Ozogamicin in Relapsed or Refractory AML. Blood 140(1):11744, 2022. e-Pub 2022.
21. Bouligny IM, Murray G, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Maher K. Healthcare Disparities Among African Americans Are Pervasive in the Treatment of AML. Blood 140(1):5281–5282, 2022. e-Pub 2022.
22. Bouligny I, Maher KR. Outcomes of Induction with Venetoclax in Combination with Decitabine, Azacitidine, or Low-Dose Cytarabine for Treatment of AML: A Real-World Retrospective Analysis. ASH 138(Supplement 1):2335, 2021.
23. Bouligny I, Maher KR. Differential Outcomes of Salvage with FLAG-IDA and Venetoclax-Based Regimens in Relapsed and Refractory Acute Myeloid Leukemia. ASH 138(Supplement 1):4424, 2021.
24. Maher KR, Bouligny I. A Retrospective Comparison of Hypomethylating Agent in Combination with Venetoclax Versus Liposomal Daunorubicin and Cytarabine in Frontline Treatment of Acute Myeloid Leukemia. ASH 138(Supplement 1):2336, 2021.
25. Maher KR, Bouligny I. Minority Health Disparities in Acute Myeloid Leukemia: A Metropolitan, Single-Center Retrospective Analysis. ASH 138(Supplement 1):1987, 2021.
26. Bouligny I, Maher KR. Outcomes of High-Intensity Versus Low-Intensity Induction in Elderly Patients with AML: A Retrospective Analysis of Real-World Outcomes. ASH 138(Supplement 1):4386, 2021.
27. Bouligny I, Maher KR. The Impact of Molecular and Cytogenetic Clonal Evolution on Survival in Relapsed/Refractory AML. ASH 138(Supplement 1):4452, 2021.

Letters to the Editor

1. Jen WY, Loghavi S, Bazinet A, Bataller A, Bouligny I, Daver NG, Issa GC, Arani N, Almanza Huante E, Maiti A, Montalban-Bravo G, Borthakur G, Short NJ, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F, Kantarjian HM, DiNardo CD, Kadia TM. Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies. Am J Hematol 100: 2118-2122, 2025.
2. Bouligny IM, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Pemmaraju N, Kadia T, Masarova L, Takahashi K, Andreeff M, Bazinet A, Yang H, Kanagal R, Pierce S, Meyer M, Huang X, Garcia-Manero G. A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms. Leukemia 39: 524-528, 2025.
3. Bouligny IM, Murray G, Ho T, Doyel M, Patel T, Boron J, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Wages NA, Grant S, Maher KR. Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia. Leuk Res 134: 107370, 2023.